Neurological Diseases

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases as well as traumatic injury.

Uncategorized

‘Mailman’ gene-editing tool carries molecule to exact ‘zip code’

HQ Team May 24, 2025: Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases.

by HealthQuill
May 24, 2025
0 Comments

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

Drugs Health Pharma

Roche to pay $42 million to Ascidian to make RNA exon editing drugs

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.